




Neogap secures SEK 87 million to advance clinical development of its personalised immunotherapy

Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has raised SEK 87 million in a financing round led by Sociaty. The capital will be used to advance the company's ongoing clinical study and to build the data required for the next stage of Neogap's development programme.



The ongoing clinical study is a first-in-human trial evaluating Neogap's personalised cell therapy in patients with advanced colorectal cancer. The primary focus is on safety and tolerability, while the study also generates early clinical and exploratory data. Several patients have been treated, and previously communicated safety data indicate that the treatment is well tolerated.

In parallel, Neogap has received approval from the Swedish Medical Products Agency to treat all patients in the study at full dose. This enables a more flexible and efficient study design. As part of its EIC grant, Neogap has, in collaboration with CDMO NorthX Biologics, developed a manufacturing framework to support later-stage clinical trials and future commercialisation.

"The capital enables us to continue advancing the ongoing clinical study and to take the next step in our development programme. Over the past year, we have reached several important milestones, including treating patients, generating initial safety data and receiving regulatory approvals. We are also seeing encouraging signals in our exploratory data. We now look forward to intensifying preparations for the next stage of clinical development," says Samuel Svensson, CEO of Neogap Therapeutics.

“Neogap is at a stage where clear progress is combined with strong potential in an area of significant medical need,” says Andreas Lindblom, Managing Partner at Societ. “The company has a unique therapeutic approach to T-cell therapy, combining personalised treatment with a scalable manufacturing process, which was an important factor behind our engagement in the financing.”

About Neogap’s cell-based immunotherapy, pTTL

pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy designed to enhance a patient’s own T cells to fight cancer. The therapy combines advanced DNA sequencing with T-cell expansion to deliver a personalised, precision-based treatment for solid tumours. The pTTL treatment is based on Neogap’s proprietary technologies, PIOR[®] and EpiTCer[®], and is currently being evaluated in a Phase I/II study in patients with advanced colorectal cancer.

European
Innovation
Council



**Co-funded by
the European Union**

Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.

For more information, please contact:

Samuel Svensson, CEO

Email: samuel.svensson@neogap.se

Phone: +46 733 54 21 94

About Neogap Therapeutics

Neogap Therapeutics is a Swedish clinical-stage biotechnology company developing personalised cancer immunotherapy using the patient’s own cells. The therapy is based on the company’s two proprietary technologies, PIOR[®] and EpiTCer[®]. PIOR[®] leverages patient-derived DNA sequencing data and machine learning to identify tumour-specific mutations. EpiTCer[®] is used to expand T cells that recognise and target the selected tumour-specific structures. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its research, please visit neogap.se and follow Neogap on [LinkedIn](#).